Competing interests
Cancer
ONCOLOGY, CANCER
Mikkael A. Sekeres holds a consulting or advisory role with Celgene, Millennium, and Syros Pharmaceuticals and received research funding from Pfizer and Takeda. Pau Montesinos is a consultant to, has received research funding from, and is on the speakers’ bureau for AbbVie, Bristol Meyers Squibb, and Pfizer; he is a consultant to and has received research funding from Menarini/Stemline, Novartis, and Takeda; he is a consultant to and on the speakers’ bureau for Jazz Pharmaceuticals and Astellas; and he is a consultant to Otsuka, Kura Oncology, Beigene, Incyte, Ryvu, and Nerviano. Jan Novak has a consulting or advisory role with Amgen, Takeda, Roche, Celgene, Pfizer, and Novartis and has received travel accommodations from Amgen and Janssen. Jianxiang Wang has an advisory role with honoraria for AbbVie. Deepa Jeyakumar received research funding from Pfizer and Jazz Pharmaceuticals. Benjamin Tomlinson and Erin Jou: nothing to disclose. David C. Taussig is supported by the National Institute for Health and Care Research (NICR) Royal Marsden/Institute of Cancer Research Biomedical Research Centre. Jiri Mayer reports research funding from AbbVie. Tadeusz Robak receives honoraria from AstraZeneca and Janssen and has a consultancy or advisory role and received research funding from Acerta, AstraZeneca, and Janssen. Hervé Dombret received honoraria or consulting fees from AbbVie, Amgen, Astellas, Celgene-BMS, Daiichi Sankyo, Incyte, Jazz Pharmaceuticals, Pfizer, and Servier and research funding from Amgen, Astellas, Celgene-Bristol Meyers Squibb, Incyte, Jazz Pharmaceuticals, and Pfizer. Akil Merchant serves on the advisory boards of Agios, Pfizer, and Takeda and received research funding from Pfizer. Naveed Shaik, Thomas O'Brien, Whijae Roh, Xueli Liu, Wendy Ma, Christine G. DiRenzo, and Geoffrey Chan are current or former employees of Pfizer and may hold stock ownership in Pfizer. Jorge E. Cortes has a consulting or advisory role with Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BioLineRx, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda and received research funding from Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun Pharma, Takeda, Tolero Pharmaceuticals, and Trovagene.